Release Date: August 30, 2024
Expiration Date: September 6, 2026
Activity Overview
Recent advances in prostate cancer screening have addressed the limitations of prostate-specific antigen (PSA) testing, which has a lack of specificity and a risk of overdiagnosis and overtreatment. New biomarker tests offer greater diagnostic accuracy by targeting specific biomarkers and potentially reducing unnecessary biopsies.
This educational activity aims to update health care professionals on advances in prostate cancer screening with the goal of improving prostate cancer risk assessment and decision-making and reducing unnecessary treatments. The Medical Crossfire format facilitates discussion in the context of evidence-based presentations, highlighting the current challenges and opportunities in the field and providing practical advice for implementing best practices.
Target Audience
This educational activity is directed toward urologists. Nurse practitioners, physician assistants, nurses, and other health care professionals involved in diagnosing patients for prostate cancer will be invited to participate as well.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Describe the inherent limitations of PSA screening in terms of specificity and prostate biopsies
- Differentiate between adjunctive tests for prostate cancer assessment with respect to their clinical effectiveness in monitoring and active surveillance
- Assess the latest clinical data regarding the role of adjunctive tests in the detection of high-grade prostate cancers
- Incorporate adjunctive tests into clinical practice for prostate cancer risk assessment based upon the most up-to-date clinical evidence

Jason Hafron, MD
Chief Medical Officer
Medical Director, Clinical Research
Michigan Institute of Urology, Solaris Health
Rochester Hills, MI
Professor of Urology
Oakland University William Beaumont School of Medicine
Auburn Hills, MI
Disclosures: Consultant/Advisor: Astellas Pharma, Immunis.AI, Janssen Biotech, Lilly, Lipella Pharmaceuticals, Lynx DX, Myriad Genetics, Myovant Sciences, Pfizer, Photocure, Promaxo, Tolmar Pharmaceuticals, UroGen Pharma; Meeting Participant/Lecturer: Amgen, Astellas Pharma, Bayer, Blue Earth Diagnostics, Dendreon Pharmaceuticals, Janssen Biotech, Lantheus, Merck & Co, Myriad Genetics, Myovant Sciences, Pfizer, PROCEPT BioRobotics, Progenics Pharmaceuticals, Tolmar Pharmaceuticals, UroGen Pharma; Scientific Study/Trial: Astellas Pharma, Dendreon Pharmaceuticals, Immunis.AI, Janssen Biotech, Lipella Pharmaceuticals, Merck & Co, miR Scientific, Myovant Sciences, Myriad Genetics, Nucleix, Pfizer.

Aaron D. Berger, MD
Chief Medical Officer
Director, Clinical Research
Associated Urological Specialists, Solaris Health
Chicago Ridge, IL
Disclosures: Consultant/Speaker: Accord BioPharma, Astellas, Bayer, Johnson & Johnson, Pfizer, Sumitomo.

Arpeet Shah, MD
Director, APP Program
Associated Urological Specialists, Solaris Health
Homewood, IL
Disclosures: Arpeet Shah, MD, has no relevant financial relationships with ineligible companies.
Faculty, Staff, and Planners’ Disclosures
The staff of Physicians’ Education Resource®, LLC, have no relevant financial relationships with ineligible companies.
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.

GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here